CompletedNCT04916626
Official study titleThe OPUS YOUNG Study. The Efficacy of Early Intervention Service Versus Treatment as Usual for Adolescents Aged 12 - 17 With First-episode Psychosis, a Pragmatic Randomized Clinical Trial
This study has finished and is no longer accepting participants.
In HellerupSchizophrenia, DepressionBehavioural studyAges 12–17
- Countries
- Denmark
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
CompletedNCT01006551
This study has finished and is no longer accepting participants.
Multiple locations, including MedfordSchizophreniaMedication studyAges 6–19
- Countries
- United States
- Sponsor
- University of North Carolina, Chapel Hill
Not recruitingISRCTN11394005
This study isn't currently recruiting.
In United KingdomSchizophreniaResearch study
- Countries
- United Kingdom
- Sponsor
- The University of Manchester
Not recruitingISRCTN49141214
This study isn't currently recruiting.
In United KingdomSchizophreniaResearch study
- Countries
- United Kingdom
- Sponsor
- Manchester Mental Health And Social Care NHS Trust
WithdrawnNCT07084831
What is this study about?Researchers are studying Xanomeline/trospium to find out how it affects memory, attention and other thinking skills in adults with schizophrenia.
This study was withdrawn before enrollment.
Multiple locations, including InnsbruckSchizophreniaMedication studyAges 18–55
- Countries
- Belgium, Austria, Czechia, + 7 others
- Sponsor
- European Group for Research In Schizophrenia
CompletedNCT04659161
Official study titleA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
CompletedNCT04738123
Official study titleA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States, Ukraine
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
CompletedNCT04457310
This study has finished and is no longer accepting participants.
Multiple locations, including New HavenSchizophreniaMedication studyAges 18–45
- Countries
- United States
- Sponsor
- Yale University
CompletedNCT07116850
Official study titleAdjunctive Intermittent Theta-Burst Stimulation for First-Episode Schizophrenia: A Randomized Clinical Trial
This study has finished and is no longer accepting participants.
In ShijiazhuangSchizophreniaMedication studyAges 18–45
- Countries
- China
- Sponsor
- The First Hospital of Hebei Medical University
CompletedNCT05414058
Official study titleAdjunctive Methylphenidate Extended Release in Patients With Schizophrenia: a Single-centre Fixed Dose Cross-over Open-label Trial to Improve Functional and Cognitive Outcomes
This study has finished and is no longer accepting participants.
In OttawaSchizophreniaMedication studyAges 18–55
- Countries
- Canada
- Sponsor
- The Royal Ottawa Mental Health Centre
CompletedNCT04046497
Official study titleEarly-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication
This study has finished and is no longer accepting participants.
Multiple locations, including HialeahSchizophreniaInterventional studyAges 15–40
- Countries
- United States
- Sponsor
- Northwell Health
CompletedNCT07141966
This study has finished and is no longer accepting participants.
In IstanbulSchizophreniaObservational studyAges 18–65
- Countries
- Türkiye
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital